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Apolipoprotein A5 (APOA5) was identiﬁed as a strong modulator of serum lipids. Moreover, an APOA5 gene −1131T>C
polymorphismhasbeenassociatedwithserumlipids,buttheresultsareinconsistentaccordingtoethnicandracialgroups.Wehave
genotyped and analyzed 1,619 outpatients of Korean oriental medicine hospitals who were classiﬁed into three Sasang constitution
groups (SCGs), So-Yang (SY), So-Eum (SE), and Tae-Eum (TE). There were no signiﬁcant diﬀerence in the distribution of
the APOA5 −1131T>C genotype among the three SCGs. Subjects with the C allele in SY and TE showed signiﬁcantly lower
serum high-density lipoprotein cholesterol (HDL-C) and higher triglyceride (TG) levels than noncarriers of the C allele. These
results show the diﬀerences in the prevalence of decreasing serum HDL-C and elevating serum TG levels along with APOA5
−1131T>C polymorphism according to SCG and suggest that SCG may act as a signiﬁcant risk factor for hypo-HDL-C-emia and
hypertriglyceridemia susceptibility.
1.Introduction
Cardiovascular disease (CVD) is one of the most common
conventional causes of death in industrialized countries, and
elevation of triglycerides (TG) levels, hypertriglyceridemia,
has been shown to be related to an increased risk of CVD
[1–5]. Serum TG levels vary among individuals due to both
environmental and genetic factors [6, 7].
The identiﬁcation of speciﬁc genetic determinants of
plasma triglyceride concentrations has been attempted, and
recently a novel member of the apolipoprotein family,
human apolipoprotein A5 (APOA5), was identiﬁed by the
comparative sequencing of the APOA1/C3/A4 gene cluster
region [8]. Functional studies of ApoA5 with mice that were
genetically modiﬁed to either overexpress or lack ApoA5
provided direct evidence that ApoA5 plays an important role
in plasma triglyceride metabolism. The plasma TG levels
in mice overexpressing a human APOA5 transgene were
one-third those in control mice and increased fourfold in
mice lacking ApoA5; overexpression of APOA5 in mice using
adenovirus markedly decreased (−70%) serum triglyceride
levels [8, 9]. Moreover, three single-nucleotide polymor-
phisms, including −1131T/C, IVS3+476G>A, and 1259T/C,
across the APOA5 locus to be signiﬁcantly associated with
plasma TG levels were identiﬁed [8]. Speciﬁcally, an SNP
−1131T>C (rs662799) in the promoter region of the APOA5
gene has been associated with elevation of plasma TG levels
in several populations of various ethnicities [8, 10–13]. In
addition, several studies have demonstrated that this SNP
was associated with reduced plasma high-density lipoprotein
cholesterol (HDL-C) levels [13–15].
Since knowledge of genetics and molecular biology has
been accumulated, interests in personalized medical care
have become important in making the best therapeutic
choice by facilitating predictions about drug eﬃcacy and
safety. Interestingly, Sasang constitutional medicine (SCM),
a unique Korean traditional therapeutic alternative form of
medicine, has already been developed with properties of2 Evidence-Based Complementary and Alternative Medicine
personalized medicine [16]. SCM is originated from the
theory that human beings are categorized into four constitu-
tions according to the traits of an individual’s temperament
and body shape, and each constitution has a diﬀerent
drug response to certain herbal medicine and diﬀerent
susceptibility to pathology [16, 17]. In SCM, therefore, each
constitution shares the similar aspects of bodily structure,
function, and metabolism, as well as psychological and
behavioral characteristics [16, 18, 19].
It has been suggested that the prevalence and relative
risk of several chronic diseases were found to diﬀer across
diﬀerent Sasang constitution groups (SCGs), and the same
disease is often treated diﬀerently for diﬀerent individuals
based on the constitutionally diﬀerentiated traits in clinical
practice [17]. Recently, several studies have described eﬀorts
to explain SCM from the perspective of genetics and the
genome-wide scale, but much controversy still remains [20–
22]. Therefore, the identiﬁcation of gene variants associated
with hypertriglyceridemia phenotypes according to SCG
might help to individualize the prognosis, treatment, and
prevention of CVD and metabolic diseases. We have recently
identiﬁed that signiﬁcant diﬀerences exist in serum lipid
proﬁles among SCGs and hypothesized that some genetic
factors may be responsible for this discrepancy. Therefore,
the aim of the study is to evaluate the association of APOA5
−1131T>C polymorphism with serum lipid levels in a large
population-based study with Korean subjects classiﬁed by
SCM.
2.MaterialsandMethods
2.1. Study Population. Data were retrospectively collected
from 20 oriental medical hospitals in Korea between 2006
and 2009. Recruited participants were outpatients who had
at least four visits. All samples and clinical information were
deposited in Databank of Sasang Constitutional Medicine
(DB-SCM) in the Korea Institute of Oriental Medicine.
TheSCGofanindividualwasdeterminedfollowingthree
procedures. Firstly, the prediagnosis of the SCG of individual
was conducted by licensed medical specialist in SCM who
have been in clinical practice at least 5 years. The specialist
of SCM considers carefully in terms of physical body shape,
appearance, temperament, and pathological symptoms of
individual to prediagnose the SCG. Secondly, participant
who constitutionally prediagnosed was treated with SCG-
speciﬁc herbal formulae according to the individual’s con-
stitution [19, 20, 23]. We included only the patients who had
beentakingherbalformulaeforatleast30daysandhadgood
medication responses, showing clear improvements in the
chief complaints and ordinary symptom without any adverse
eﬀects. It has been reported that the prescription which was
not suitable for the SCG induced adverse reactions such
as indigestion, stomachache, and evacuation troubles [24].
Finally, the SCG of individual was clinically conﬁrmed by the
specialist of SCM based on the medical chart review.
To avoid potential confounding of the association
betweentheAPOA5 −1131T>Cpolymorphismandpreexist-
ing diseases instead of SCGs, subjects with a history of CVD,
hypertension, cancer, liver disease and diabetes in case report
form(CVD)wereexcluded.SincethepopulationofTae-Yang
isextremelylow(0.03%)[25]andinpresentstudytherewere
only 27 participants (0.01%), we conducted analysis on three
SCGs: SY, SE, and TE. Finally, a total of 1,619 patients were
analyzed, including SY (n = 546), SE (n = 405), and TE
(n = 668).
Each subject’s weight and height were measured in
kilograms and in meters, respectively, and the corresponding
bodymassindex(BMI)wascalculatedbydividingtheweight
by the square of the height. Fasting blood samples were col-
lected via venipuncture in the morning after a fast of at least
8 hours. About 5mL of venous blood were collected from
each subject, and serum was separated for further analysis
for total fasting blood glucose (FBG), total cholesterol, TG,
HDL-C, and low-density lipoprotein cholesterol (LDL-C).
All subjects gave written informed consent, and the ethical
committee of our institution approved the study.
2.2. Genotyping of Single-Nucleotide Polymorphism. The
genotyping of APOA5 −1131T>C polymorphism was deter-
mined with a utilization of an unlabelled oligonucleotide
probe (UOP) that spans the polymorphic nucleotide. The
UOP was designed from a perfectly matched duplex with the
Ta l l e l eo fAPOA5 −1131. Brieﬂy, small segments of genomic
sequence spanning the APOA5 −1131T>Cp o l y m o r p h i cs i t e
were ampliﬁed by PCR using 50ng of genomic DNAs as
a template and a set of primers (APOA5-F1 ACTCTG-
AGCCCCAGGAAC, APOA5-R1 GAGTGGAGTTCAGCT-
TTTCC). PCR ampliﬁcation was performed via a heating
cycle (50◦Cf o r2m i na n d9 5 ◦C for 10 min), followed by
an amplifying cycle (40 cycles of 95◦C for 20 seconds, 56◦C
for 20 seconds, and 72◦C for 20 seconds) in a thermal cycler
(C1000, Bio-Rad).
The PCR product was diluted with two volumes of
distilled water, and the diluent was mixed with six volumes
of probe solution containing 1µMo fU O P ,5 µMo fS y t o
9 (InvitrogenTM), 12.5mM of EDTA, and 10mM of Tris
(pH 8.0) and were subsequently subjected to a thermal
reaction for genotyping using a Lightcycler 2.0 instrument
(Roche Diagnostics). The thermal reaction consists of a
denaturation step at 95◦C for 5 seconds, an annealing step
at 60◦C for 1 minute to allow annealing of complementary
strands (UOP, APOA5-S AGCTTTTCCTCATGGGGCAA-
ATCTCACTT), and a melting step with a gradual increase
of temperature at a rate of 0.1◦C/second until 95◦C, when
ﬂ u o r e s c e n c ee m i s s i o n sw e r er e a d .T h eg e n o t yp eo fe a c hP C R
product was then determined from three melting patterns
(major homozygote, heterozygote, and minor homozygote)
based on the temperature where the corresponding UOP
melts away.
2.3. Statistics. The quantitative variables were presented
as mean ± standard deviation. The allele frequency of
APOA5 −1131T>C polymorphism was determined by gene
counting. We used a Chi-square analysis to evaluate whether
APOA5 −1131T>C polymorphism was in Hardy-Weinberg
equilibrium in the population. Student’s t-test was used toEvidence-Based Complementary and Alternative Medicine 3
analyze the diﬀerence between genders. Analysis of variance
(ANOVA) was used to analyze the diﬀerence among the
SCGs. Analysis of covariance (ANCOVA) is used to adjust
eﬀect of age and sex in identifying analysis for diﬀerence
among the SCGs.
Multiple regression analysis was used to identify signiﬁ-
cantvariablesaﬀectedbygenotypeofAPOA5,andeﬀectsizes
(slope) were presented as changes in minor allele carriage.
Eﬀects of sex and age are adjusted in multiple regression
models. A P-value less than 0.05 was considered statistically
signiﬁcant.AllstatisticalanalyseswereperformedusingSPSS
(SPSS Inc., Chicago, IL; V14.0 for Windows).
3. Results
3.1. Clinical Characteristics of the Study Population According
to APOA5 −1131T>CG en o typ e . A total of 1,619 individuals,
595 males and 1024 females, were enrolled in this study. The
general clinical characteristics of study subjects, including
age, BMI, FBG, HDL-C, LDL-C, total cholesterol, and TG,
for this study as a total and according to gender were
presented in Table 1. The genotype distribution of APOA5
−1131T>Camongthe1,619subjectsanalyzedwasasfollows:
765 subjects (269 males and 496 females) were homozygous
for the T allele (TT), 712 subjects (269 males and 443
females) were heterozygous (TC), and 142 subjects (57 males
and 85 females) were homozygous for the C allele (CC).
The minor allele (C) frequency of APOA5 −1131T>Cw a s
0.305, and the genotype distributions did not deviate from
the Hardy-Weinberg equilibrium.
To address the association and impact of APOA5
−1131T>C polymorphism on the lipid proﬁle, we evaluated
the mean values of HDL-C, LDL-C, total cholesterol, and
TG from each genotype and performed multiple regression
analysis. The association result indicated that there was a
signiﬁcant association between serum HDL-C levels and
the APOA5 −1131T>Cg e n o t y p e( e ﬀect = −1.602mg/dL,
P = 3.61E−04). In addition, the TC genotype group had
lower serum HDL-C levels (45.76 ± 12.17mg/dL) than the
TT genotype group (46.91 ± 11.68mg/dL), and the CC
genotype group had the lowest serum HDL-C levels (43.44
± 10.33mg/dL).
The association of APOA5 −1131T>Cw i t hs e r u mT G
was also signiﬁcant in an additive genetic model (eﬀect
= 18.792mg/dL, P = 2.94E−09). The TC genotype group
showed higher serum TG levels (131.66 ± 86.23mg/dL) than
the TT genotype group (120.85 ± 69.71mg/dL), and the
CC genotype group showed the highest serum TG levels
(166.8 ± 122.26mg/dL). However, there were no signiﬁcant
diﬀerences in BMI, FBG, LDL-C, and total cholesterol in
these genotype groups (Table 2).
Since it has been reported that gender is an important
impact factor to the correlation of serum APOA5 with HDL-
Ca n dT G[ 26–28], we reanalyzed separately by gender.
Interestingly, both in male and female subjects, the C
allele had relations with higher levels of TG (in male
eﬀect = 30.208mg/dL, P = 6.47E−07; in female eﬀect =
10.355mg/dL, P = 0.002), but the minor allele had lowering
eﬀects on the levels of HDL-C only for males (eﬀect =
−2.124mg/dL, P = 0.001; Table 3).
3.2. Association of APOA5 −1131T>C Genotype with Clinical
Parameters in SCGs. Since serum triglyceride (TG) con-
centrations reﬂect a complex interaction between multiple
genetic and environmental factors, we hypothesized that the
polymorphism of APOA5 −1131T>C would aﬀect serum
TG levels diﬀerently as a risk factor among SCGs. To
further deﬁne the association and relative risk of hyper-
triglyceridemiaconferredbySCMthatpredisposetoelevated
plasma triglyceride TG concentrations, 1,619 individuals
were classiﬁed into three constitutions groups and gender, as
describedinSection2.Theclinicalcharacteristicsofthethree
SCGs separated by gender were described in Table 4.T h e r e
was no signiﬁcant diﬀerence in the distribution of gender
amongthethreeSCGsbytheChi-squaretest(P = 0.132).We
found statistically signiﬁcant interconstitutional variations
in BMI, FBG, HDL-C, LDL-C, total cholesterol, and TG
(Table 4). Interestingly, the TE group displayed signiﬁcantly
elevated BMI, FBG, LDL-C, total cholesterol, and TG, and
depressed HDL-C compared to the SY and SE groups.
The minor allele frequency of the APOA5 −1131T>C
was 0.291, 0.299, and 0.325 in SE, SY, and TE, respectively.
There was no signiﬁcant diﬀerence in the distribution of the
APOA5 −1131T>C genotype among the three SCGs by the
Chi-square test (P = 0.133). The distribution of genotype
was in the Hardy-Weinberg equilibrium although separated
by SCGs. Interestingly, there was a signiﬁcant association
between theserumHDL-Clevelsand theAPOA5 −1131T>C
genotype in SY and TE groups (Table 5). Subjects with the
C allele in the SY and TE groups showed signiﬁcant lower
serum HDL-C levels than noncarriers of the C allele in an
additive model (in SY, eﬀect = −1.602mg/dL, P = 0.03; in
TE, eﬀect = −1.659mg/dL, P = 0.008). In addition to HDL-
C, the impact of the APOA5 −1131T>C genotype on the
serum TG levels was also observed in the SY and TE groups,
but not in the SE group (in SY, eﬀect = 24.43mg/dL, P =
3.36E−06; in TE, eﬀect = 17.155mg/dL, P = 0.001). On the
other hand, BMI, LDL-C, and total cholesterol were not sig-
niﬁcantly diﬀerent according to genotypes among the SCGs.
4. Discussion
ThepolymorphismofAPOA5−1131T>Chasbeensuggested
as a potential genetic factor involved in elevated serum
triglyceride levels and a predictor of the risk and incidence
of CVD [4, 5, 8]. In the present study, we investigated the
rolesoftheAPOA5 −1131T>Cpolymorphisminserumlipid
levels in the Korean population.
The C-allele minor frequency of our study popula-
tion (0.3048) was consistent with the frequency previ-
ously reported for Korean subjects [29, 30]. Our study
demonstrated a signiﬁcant association between the APOA5
−1131T>C polymorphism and serum TG and HDL-C
levels (Table 2), reemphasizing that the APOA5 −1131T>C
polymorphism has a signiﬁcant impact on both serumHDL-
C and TG levels. Although there are still discrepant results4 Evidence-Based Complementary and Alternative Medicine
Table 1: Clinical and biochemical characteristics of the study subjects.
Variables Mean ± SD P-value
Male (n = 595) Female (n = 1024) Total (n = 1619)
Age (years) 47.38 ± 14.88 48.45 ± 14.95 48.06 ± 14.93 0.07
BMI (kg/m2) 24.02 ± 3.3 23.17 ± 3.38 23.49 ± 3.37 6.93E−06
FBG (mg/dL) 102.49 ± 30.87 96.45 ± 25.23 98.66 ± 27.57 6.63E−05
HDL-C (mg/dL) 41.82 ± 10.28 48.66 ± 11.98 46.15 ± 11.85 1.82E−31
LDL-C (mg/dL) 106.22 ± 29.03 106.85 ± 30.16 106.62 ± 29.74 0.51
Total cholesterol (mg/dL) 185.53 ± 33.79 189.65 ± 34.45 188.14 ± 34.26 0.01
TG (mg/dL) 149.97 ± 96.53 117.48 ± 72.61 129.38 ± 83.64 2.51E−14
Values are indicated as the mean ± standard deviation.
P-value: Student’s t-test result.
Abbreviations: BMI, body mass index; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
TG, triglyceride.
Table 2: Clinical and biochemical characteristics according to the APOA5 −1131T>C polymorphism and association of the APOA5
−1131T>C polymorphism with BMI, FBG, and serum lipid variables in the study population.
Variables Mean ± SD Multiple regression
TT (n = 765) TC (n = 712) CC (n = 142) Slope 95% CI of slope P-value
BMI (kg/m2) 23.6 ± 3.42 23.37 ± 3.31 23.93 ± 3.31 0.04 −0.211 0.291 0.755
FBG (mg/dL) 99.4 ± 29.95 98.02 ± 26.29 96.55 ± 18.37 −1.185 −3.245 0.875 0.259
HDL-C (mg/dL) 46.91 ± 11.68 45.76 ± 12.17 43.44 ± 10.33 −1.602 −2.481 −0.723 3.61E−04
LDL-C (mg/dL) 107.28 ± 28.47 105.49 ± 30.98 108.95 ± 28.76 −0.022 −2.247 2.203 0.984
Total cholesterol (mg/dL) 188.5 ± 32.68 186.87 ± 35.45 192.87 ± 35.39 0.845 −1.728 3.417 0.52
TG (mg/dL) 120.85 ± 69.71 131.66 ± 86.23 166.8 ± 122.26 18.792 12.616 24.968 2.94E−09
Values are indicated as the mean ± standard deviation.
P-value: multiple regression analysis result.
Bold indicates statistically signiﬁcant (P<0.05).
Abbreviations: CI, conﬁdence interval; BMI, body mass index; FBG, fasting blood glucose HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; TG, triglyceride.
Table 3: Association of the APOA5 −1131T>C polymorphism with BMI, FBG, and serum lipid variables according to gender in study
population.
Variables Gender Mean ± SD Multiple regression
TT TC CC Slope 95% CI of slope P-value
BMI (kg/m2) Male 24.14 ± 3.41 23.84 ± 3.29 24.26 ± 2.98 −0.058 −0.469 0.353 0.781
Female 23.3 ± 3.39 23.09 ± 3.3 23.72 ± 3.51 0.052 −0.26 0.363 0.744
FBG (mg/dL) Male 103.81 ± 35.87 101.16 ± 25.92 98.65 ± 20.74 −2.149 −5.866 1.568 0.257
Female 97.01 ± 25.91 96.12 ± 26.36 95.14 ± 16.58 −0.815 −3.231 1.601 0.508
HDL-C (mg/dL) Male 42.82 ± 10.46 41.29 ± 10.31 38.32 ± 7.09 −2.124 −3.362 −0.887 0.001
Female 49.13 ± 11.72 48.48 ± 12.42 46.88 ± 10.76 −0.987 −2.106 0.131 0.084
LDL-C (mg/dL) Male 107.79 ± 28.19 104.48 ± 30.24 104.67 ± 27.97 −2.262 −5.882 1.358 0.22
Female 107 ± 28.65 106.1 ± 31.44 111.82 ± 29.09 1.177 −1.615 3.969 0.408
Total cholesterol (mg/dL) Male 186.3 ± 32.22 183.3 ± 35.19 188.67 ± 36.28 −0.481 −4.71 3.747 0.823
Female 189.7 ± 32.89 189.04 ± 35.46 195.69 ± 34.71 1.62 −1.582 4.822 0.321
TG (mg/dL) Male 135.58 ± 71.94 152.35 ± 95.84 209.95 ± 163.59 30.208 18.416 42 6.47E−07
Female 112.86 ± 67.2 119.1 ± 77.28 137.87 ± 71.68 10.355 3.752 16.958 0.002
Values are indicated as the mean ± standard deviation.
P-value: multiple regression analysis result.
Bold indicates statistically signiﬁcant (P<0.05).
Abbreviations: CI, conﬁdence interval; BMI, body mass index; FBG, fasting blood glucose HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; TG, triglyceride.Evidence-Based Complementary and Alternative Medicine 5
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Table 5: Association of the APOA5 −1131T>C polymorphism with BMI, FBG, and serum lipid variables according to SCG in study
population.
Variables Constitution Mean ± SD Multiple regression
TT TC CC Slope 95% CI of slope P-value
BMI (kg/m2)
SY 22.81 ± 3.12 22.77 ± 2.65 23.25 ± 2.66 0.132 −0.224 0.489 0.465
SE 21.56 ± 2.7 21.21 ± 2.5 21.63 ± 3.13 −0.098 −0.518 0.322 0.647
TE 25.42 ± 3.12 25.35 ± 3.17 25.38 ± 3.22 −0.049 −0.412 0.314 0.79
FBG (mg/dL)
SY 100.23 ± 32.1 98.06 ± 29.59 98.31 ± 17.52 −1.256 −5.022 2.51 0.513
SE 93.4 ± 20.04 93.34 ± 17.35 93.54 ± 16.09 0.112 −2.862 3.086 0.941
TE 102.25 ± 32.46 101.17 ± 28.02 96.19 ± 19.92 −2.45 −5.826 0.926 0.155
HDL-C (mg/dL)
SY 47.62 ± 11.43 46.21 ± 12.93 44.26 ± 9.77 −1.602 −3.043 −0.16 0.03
SE 49.24 ± 12.07 49.42 ± 11.55 46.29 ± 10.65 −0.537 −2.368 1.294 0.564
TE 44.97 ± 11.35 42.91 ± 11.24 41.69 ± 10.5 −1.659 −2.883 −0.436 0.008
LDL-C (mg/dL)
SY 106.75 ± 29.92 103.34 ± 28.71 103.39 ± 29.99 −1.873 −5.562 1.816 0.319
SE 100.35 ± 26.6 101.7 ± 28.43 110.71 ± 28.78 3.957 −0.482 8.396 0.081
TE 111.76 ± 27.56 109.82 ± 33.88 112.98 ± 27.36 −0.37 −3.9 3.159 0.837
Total cholesterol (mg/dL)
SY 188.63 ± 33.64 184.87 ± 33.12 189.57 ± 36.75 −0.591 −4.836 3.654 0.785
SE 180.76 ± 31.32 182.46 ± 32.27 192.25 ± 30.32 4.717 −0.395 9.829 0.07
TE 192.94 ± 31.91 191.51 ± 38.77 195.89 ± 36.24 0.419 −3.683 4.52 0.841
TG (mg/dL)
SY 117.68 ± 69.29 130.47 ± 83.47 179.48 ± 130.64 24.43 14.212 34.648 3.36E−06
SE 98.86 ± 51.96 102.62 ± 50.78 118.08 ± 74.47 7.99 −0.183 16.163 0.055
TE 136.31 ± 75.28 152.41 ± 100.8 174.38 ± 126.37 17.155 6.696 27.614 0.001
Values are indicated as the mean ± standard deviation.
P-value: multiple regression analysis result.
Bold indicates statistically signiﬁcant (P<0.05).
Abbreviations: CI, conﬁdence interval; SY, So-Yang; SE, So-Eum; TE, Tae-Eum; BMI, body mass index; FBG, fasting blood glucose; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.
regarding to the association of the APOA5 −1131T>Cw i t h
serum HDL-C levels [8, 10, 28, 31], interestingly, our study
revealed that the HDL-C levels were signiﬁcantly lowered
through the per-allele carriages. The serum HDL-C levels of
subjectswiththeCC genotype were7.4%lower thanthoseof
subjects with the TT genotype.
Furthermore, it should be noted that we observed the
impact of gender on genotype-phenotype response in serum
HDL-C levels since the APOA5 −1131T>Cp o l y m o r p h i s m
was only signiﬁcantly associated with serum HDL-C in male
subjects, not in female subjects (Table 3). These results
contradict the report that the HDL-C-lowering eﬀect of the
APOA5 −1131T>Cp o l y m o r p h i s mi sl e s si nm a l et h a ni n
female [31, 32], but is consistent with the results of a recent
meta-analysis [13] in that the eﬀect of variants in the APOA5
gene on plasma HDL-C was more pronounced in males than
in female subjects.
Several studies conducted with a large population have
consistently shown that the APOA5 −1131T>Cp o l y m o r -
phism is strongly associated with quantitative diﬀerences
in serum TG levels [8, 11, 15, 28–30]. Our results also
indicated that the APOA5 −1131T>Cp o l y m o r p h i s mi s
associated with elevated serum TG levels in the Korean
populations investigated (Table 2), although the impact
varied depending on gender (Table 3). The serum TG levels
of TC and CC were 8.9% and 38% higher than noncarriers
(TT) in total population, respectively. In males, the serum
TG levels of TC and CC were 12.37% and 54.85% higher
than noncarriers (TT), respectively, whereas, in females, the
serum TG levels of TC and CC were 5.52% and 22.16%
higher than noncarriers (TT), respectively, suggesting that
the impact of the APOA5 g e n o t y p eo ns e r u mT Gl e v e l sm a y
be gender dependent.
One of the previously reported variants showing an
association with TG [8], rs2266788 (1259T/C), was found
to be tightly linked with rs180349 (A>T) SNP (r2 =
0.85, D  = 0.94) in HapMap Han Chinese and Japanese
HapMap populations (HapMap-HCB and JPT) [33]v i a
the Haploview program (version 4.2) whereas rs226679 is
tightly linked with rs481843 SNP in Caucasian HapMap
population (HapMap-CEU) [34]. The T allele of rs180349
was signiﬁcantly associated with TC and TG in 979 Koreans
by the aﬀymetrix chip analysis (table not shown, eﬀect =
5.39mg/dL, P = 3.7E−3f o rT C ;e ﬀect = 19.48mg/dL, P =
6.12E−6 for TG). This rs180349 SNP was also tightly linked
with rs662799 (APOA5 −1131T>C )b a s e do nH a p M a pH C B
and JPT (r2 = 0.69, D  = 0.90). Therefore, the APOA5
−1131T>C polymorphism may be in same haplotype block
with 1259T/C polymorphism via rs180349 SNP, conﬁrming
the genetic eﬀect of APOA5 gene on TG in Koreans. There
were no gender-speciﬁc associations with the SNP rs180349.
In our study, serum TG levels were higher in TE followed
by SY and SE, but the HDL-C levels were reversed (Table 4),
leading us to analyze the diﬀerences in allele frequency of
the APOA5 −1131T>C among the SCGs; but there were
no statistically signiﬁcant diﬀerences. However, multipleEvidence-Based Complementary and Alternative Medicine 7
regression analysis showed that eﬀect of APOA5 −1131T>C
polymorphism on serum HDL-C lowering and TG elevating
were greater in the TE and SY groups than the SE group. It
is interesting that these eﬀects were signiﬁcant only in the SY
and TE groups not in the SE group.
These ﬁndings have a thread of connection with the
theory of SCM that there are diﬀerences in the suscep-
tibility to pathological conditions according to SCG [35].
Speculatively, it is suggested that the APOA5 −1131T>C
polymorphism do not produce categorical dyslipidemia but
functions as modiﬁer for serum HDL-C and TG levels
according to SCG. Moreover, these diﬀerential eﬀects of
APOA5 −1131T>C polymorphism on serum lipids levels
are reminiscent of previous reports that the prevalence and
relative risk of several chronic disease were found to diﬀer
across diﬀerent SCGs and the SCG showed signiﬁcant and
independent association with diabetes mellitus [17, 35, 36].
The diﬀerences in the prevalence of decreasing serum HDL-
C and elevating serum TG levels according to SCG together
with APOA5 −1131T>C polymorphism suggest that SCG
may act as a signiﬁcant risk factor of hypo-HDL-C-emia
and hypertriglyceridemia susceptibility. Moreover, the eﬀect
of rs180349 on TG levels were exclusively enriched in the
group of SY type (table not shown, eﬀect = 30.76mg/dL,
P = 2.23E−5). Therefore, we believe that comprehensive
knowledge of SCG and genotyping individuals for APOA5
polymorphisms may be helpful in predicting disease suscep-
tibility.
5. Conclusions
In conclusion, the association of APOA5 −1131T>Cp o l y -
morphism with serum HDL-C and TG levels were clearly
established in Korean subjects in the current study. In
particular, the C allele of APOA5 −1131 was associated with
lower serum HDL-C and higher TG in SY and TE but
not in SE subjects. Therefore, we suggest that this genetic
marker, together with SCG, may help in the identiﬁcation
of subjects who are highly susceptible to hypo-HDL-C-emia
and hypertriglyceridemia, so that preventive care may be
undertaken to reduce CVD.
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